Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Exenatide and rare adverse events.

× No keyword cloud information.

38 in total

1. Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents.

Authors: Krystyna Tatarkiewicz; Pamela A Smith; Emmanuel J Sablan; Clara J Polizzi; Donald E Aumann; Christiane Villescaz; Diane M Hargrove; Bronislava R Gedulin; Melissa G W Lu; Lisa Adams; Tina Whisenant; Denis Roy; David G Parkes
Journal: Am J Physiol Endocrinol Metab Date: 2010-10-05 Impact factor: 4.310

2. Present and Prospective Pharmacotherapy for the Management of Patients with Type 2 Diabetes.

Authors: Leonor Corsino; Mary Elizabeth Cox; Jennifer Rowel; Jennifer B Green
Journal: Clin Med Ther Date: 2009-08-27

Review 3. Incretin-based therapies for type 2 diabetes mellitus.

Authors: Julie A Lovshin; Daniel J Drucker
Journal: Nat Rev Endocrinol Date: 2009-05 Impact factor: 43.330

Review 4. Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences.

Authors: Roberta Baetta; Alberto Corsini
Journal: Drugs Date: 2011-07-30 Impact factor: 9.546

5. Multivalent activation of GLP-1 and sulfonylurea receptors modulates β-cell second-messenger signaling and insulin secretion.

Authors: Nathaniel J Hart; Craig Weber; Klearchos K Papas; Sean W Limesand; Josef Vagner; Ronald M Lynch
Journal: Am J Physiol Cell Physiol Date: 2018-11-07 Impact factor: 4.249

10. Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice.

Authors: Jacqueline A Koehler; Laurie L Baggio; Benjamin J Lamont; Safina Ali; Daniel J Drucker
Journal: Diabetes Date: 2009-06-09 Impact factor: 9.461

Exenatide and rare adverse events.

1. Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents.

2. Present and Prospective Pharmacotherapy for the Management of Patients with Type 2 Diabetes.

Review 3. Incretin-based therapies for type 2 diabetes mellitus.

Review 4. Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences.

5. Multivalent activation of GLP-1 and sulfonylurea receptors modulates β-cell second-messenger signaling and insulin secretion.

Review 6. Obesity treatment: novel peripheral targets.

Review 7. Benefit-risk assessment of exenatide in the therapy of type 2 diabetes mellitus.

Review 8. The evolving place of incretin-based therapies in type 2 diabetes.

9. Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits.

10. Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice.